CRISPR Therapeutics AG
CHFinancials
Valuation Metrics
CRISPR Therapeutics AG's Market Cap is $4.96B. At end of 2025 it was $4.72B. Ranked #1322 of 3,116 in US market (top 42%), #444 of 1,472 on NASDAQ (top 30%), #77 of 265 in Pharmaceuticals, Biotechnology & Life Sciences (top 29%) by Market Cap.
Investment Metrics(as of 2026-10-30)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $4.96B | US#1,322/3,116 Sec#77/265 |
| Revenue | $13M | US#2,797/3,116 Sec#166/265 |
| Net Income | $-451M | US—/3,116 Sec—/265 |
| Total Assets | $2.65B | US#1,890/3,116 Sec#50/265 |
| Net Assets | $1.75B | US#1,341/3,116 Sec#42/265 |
| Employees | 393 | US#2,333/3,116 Sec#95/265 |
| Value | ||
| P/B | 2.84x | US#1,746/3,116 Sec#96/265 |
| P/S | 370.18x | US#2,968/3,116 Sec#190/265 |
| FCF Yield | -9.70% | US—/3,116 Sec—/265 |
| Profitability | ||
| ROE | -25.83% | US#2,530/3,116 Sec#109/265 |
| ROA | -17.02% | US#2,754/3,116 Sec#124/265 |
| Op. Margin | -3971.53% | US#2,826/3,116 Sec#175/265 |
| Revenue Growth | -64.15% | US#2,706/3,116 Sec#166/265 |
| Financial Health | ||
| Debt Ratio | 51.77% | US#591/3,116 Sec#140/265 |
| Total Debt | $784M | US#1,648/3,116 Sec#50/265 |
| FCF | $-481M | US#2,897/3,116 Sec#251/265 |
| Cash | $291M | US#1,438/3,116 Sec#81/265 |
| Current Ratio | 17.85x | US#131/3,116 Sec#33/265 |
| Performance | ||
| 1Y Return | -15.88% | US#2,229/3,116 Sec#181/265 |
| 1M Return | -7.09% | US#2,157/3,116 Sec#148/265 |
| From 52W High | -20.61% | US#1,408/3,116 Sec#76/265 |
| 1Y MDD | -28.45% | US#1,365/3,116 Sec#67/265 |
| Trading | ||
| Volume | 957,588 shares | US#1,301/3,116 Sec#125/265 |
| Trading Value | $50M | US#1,084/3,116 Sec#69/265 |
| Per Share | ||
| EPS | $-4.68 | US—/3,116 Sec—/265 |
| BPS | $18.11 | US#1,339/3,116 Sec#35/265 |
Company Info
CRISPR Therapeutics AG (CRSP) is a biotechnology firm dedicated to pioneering gene-based medicines for severe diseases. The company achieves this through its exclusive Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) technology, which enables precise and targeted alterations to an organism's genetic code. Its extensive pipeline includes therapeutic candidates spanning multiple medical areas, such as blood disorders (hemoglobinopathies), various cancers (oncology), regenerative medicine, and rare conditions. The company's flagship investigational therapy is CTX001, an ex vivo CRISPR gene-edited treatment. This therapy aims to benefit patients with transfusion-dependent beta-thalassemia or severe sickle cell disease by modifying their own hematopoietic stem cells to markedly boost the production of fetal hemoglobin within red blood cells. CRISPR Therapeutics is also advancing several other genetically engineered allogeneic (donor-sourced) CAR-T investigational therapies: CTX110, designed to combat cluster of differentiation 19-positive malignancies; CTX120, which targets B-cell maturation antigen for multiple myeloma that has relapsed or proven resistant to previous treatments; and CTX130, focused on Cluster of Differentiation 70 for a spectrum of solid tumors and blood cancers. Furthermore, the company is developing VCTX210, an immune-evasive, gene-edited stem cell-derived product candidate for treating type 1 diabetes. It is also pursuing various in vivo gene-editing initiatives aimed at addressing disorders affecting the liver, lungs, muscles, and central nervous system. The company has forged strategic alliances with significant partners, including Bayer Healthcare LLC, Vertex Pharmaceuticals Incorporated, ViaCyte, Inc., Nkarta, Inc., and Capsida Biotherapeutics. CRISPR Therapeutics AG was established in 2013 and maintains its headquarters in Zug, Switzerland.